Cormorant Asset Management, LP Janux Therapeutics, Inc. Transaction History
Cormorant Asset Management, LP
- $1.27 Billion
- Q4 2024
A detailed history of Cormorant Asset Management, LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 2,100,000 shares of JANX stock, worth $76.4 Million. This represents 8.88% of its overall portfolio holdings.
Number of Shares
2,100,000
Previous 1,050,000
100.0%
Holding current value
$76.4 Million
Previous $47.7 Million
135.71%
% of portfolio
8.88%
Previous 3.34%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
207Shares Held
50.6MCall Options Held
158KPut Options Held
697K-
Ra Capital Management, L.P. Boston, MA10.4MShares$377 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$130 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$128 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$111 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$85.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.52B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...